Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Dermira Inc (DERM)

Dermira Inc (DERM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,044,350
  • Shares Outstanding, K 54,521
  • Annual Sales, $ 42,340 K
  • Annual Income, $ -221,540 K
  • 60-Month Beta 1.62
  • Price/Sales 11.23
  • Price/Cash Flow N/A
  • Price/Book 71.94

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -1.39
  • Number of Estimates 2
  • High Estimate -1.14
  • Low Estimate -1.64
  • Prior Year -1.70
  • Growth Rate Est. (year over year) +18.24%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.50 +53.24%
on 01/06/20
19.48 -1.67%
on 01/10/20
+6.13 (+47.01%)
since 12/17/19
3-Month
5.80 +230.26%
on 10/18/19
19.48 -1.67%
on 01/10/20
+13.47 (+236.64%)
since 10/17/19
52-Week
5.25 +264.86%
on 10/16/19
19.48 -1.67%
on 01/10/20
+12.31 (+179.64%)
since 01/17/19

Most Recent Stories

More News
DERM, CRCM, LOGM, and WAAS SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts

Rigrodsky & Long, P.A. announces that it is investigating:

DERM : 19.16 (+0.03%)
LOGM : 86.55 (+0.46%)
CRCM : 14.98 (unch)
WAAS : 26.87 (-0.33%)
Bragar Eagel & Squire, P.C. Announces that it Is Investigating the Boards of Directors of Dermira, Primo Water, Hexcel, and Pope Resources on behalf of Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. announces to investors that it is investigating potential claims on behalf of stockholders of Dermira, Inc. (NASDAQ: DERM), Primo Water Corporation (NASDAQ: PRMW), Hexcel Corporation...

DERM : 19.16 (+0.03%)
PRMW : 14.67 (-0.24%)
HXL : 77.75 (-0.55%)
POPE : 125.26 (-0.94%)
Moore Kuehn, PLLC Encourages PRMW, DERM, CBB, and HABT Investors to Contact Firm

Moore Kuehn, PLLC, a securities law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders....

PRMW : 14.67 (-0.24%)
DERM : 19.16 (+0.03%)
CBB : 11.44 (+2.69%)
HABT : 13.92 (-0.36%)
Lilly to Buy Dermira for $1.1B, Add Phase III Eczema Candidate

Lilly (LLY) offers to buy Dermira for $1.1 billion to add the latter's late-stage candidate for atopic dermatitis/eczema, lebrikizumab.

SNY : 51.24 (+0.10%)
LLY : 139.58 (-1.31%)
REGN : 385.94 (+0.10%)
DERM : 19.16 (+0.03%)
Grubhub, Six Flags fall, Nektar, Infosys rise

NEW YORK (AP) — Stocks that moved heavily or traded substantially on Friday:

DERM : 19.16 (+0.03%)
LLY : 139.58 (-1.31%)
INFY : 10.88 (+0.28%)
URBN : 26.93 (+0.11%)
SIX : 37.87 (-0.86%)
SNX : 146.86 (-1.94%)
GRUB : 55.98 (-0.48%)
SHAREHOLDER ALERT: WeissLaw LLP Investigates Dermira, Inc.

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Dermira, Inc. ("DERM" or the "Company") (NASDAQ: DERM) in connection with the...

DERM : 19.16 (+0.03%)
LLY : 139.58 (-1.31%)
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of DERMIRA, INC. - DERM

Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Dermira, Inc. ("Dermira"...

LLY : 139.58 (-1.31%)
DERM : 19.16 (+0.03%)
DERMIRA MERGER INVESTIGATION: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Dermira, Inc. is Fair to Shareholders; Investors are Encouraged to Contact the Firm - DERM

Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Dermira, Inc. (NASDAQ: DERM) to Eli Lilly and Company ("Eli Lilly") for $18.75 per share is fair to Dermira shareholders....

LLY : 139.58 (-1.31%)
DERM : 19.16 (+0.03%)
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Dermira, Inc.

Rowley Law PLLC is investigating potential securities law violations by Dermira, Inc. (NASDAQ: DERM) and its board of directors concerning the proposed acquisition of the company by Eli Lilly and Company...

DERM : 19.16 (+0.03%)
LLY : 139.58 (-1.31%)
The Zacks Analyst Blog Highlights: Agile Therapeutics, Air Industries, Dermira, Microbot Medical and Cassava Sciences

The Zacks Analyst Blog Highlights: Agile Therapeutics, Air Industries, Dermira, Microbot Medical and Cassava Sciences

AIRI : 2.15 (-14.68%)
DERM : 19.16 (+0.03%)
AGRX : 2.82 (-3.75%)
MBOT : 12.47 (+2.72%)
SAVA : 8.25 (-4.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade DERM with:

Business Summary

Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage...

See More

Key Turning Points

2nd Resistance Point 19.24
1st Resistance Point 19.20
Last Price 19.16
1st Support Level 19.12
2nd Support Level 19.08

See More

52-Week High 19.48
Last Price 19.16
Fibonacci 61.8% 14.04
Fibonacci 50% 12.36
Fibonacci 38.2% 10.69
52-Week Low 5.25

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar